Recent Updates
Recently added Catalysts

Catalyst Pharmaceuticals, Inc.

CPRXFDA catalysts, PDUFA dates & pipeline intelligence
$31.49
▲ 0 · 0%

Last traded Jul 14, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CPRX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $19.0552W HIGH $32.56
Volume
15.45 M
Value Traded
54.43 M
Short % Float
0.29%
Days to Cover
1.0
+0.29%Week
+21.07%1 Month
+28.11%3 Month
+37.83%6 Month
+453.76%5 Year
+421%All Time

Cash Data

Unlock CPRX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.83 B
EPS (TTM)
1.81
P/E Ratio
17.97
Ent. Value
3.07 B
Total Shares
122.43 M
Float Shares
115.58 M
Insiders
8.80%
Institutions
83.42%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every CPRX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CPRX Catalyst Timeline

Dated clinical, regulatory and corporate events for Catalyst Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Catalyst Pharmaceuticals, Inc.

971Total events
2Upcoming
242Tier-1 (high impact)
2010 to 2037Coverage

Upcoming catalysts 2

T1Patent Expiry
Subscribe to view catalyst details
AGAMREEApproved
T1Patent Expiry
Subscribe to view catalyst details
FIRDAPSEApproved

Event history 50

▲AcquiredCorporate
Angelini Pharma completes acquisition of Catalyst Pharmaceuticals
source ↗
▲Topline ReadoutAGAMREEApprovedClinical Data
Topline results from Phase 1 study of AGAMREE
chronic inflammatory rare diseasessource ↗
◆AcquisitionCorporate
Acquisition expected to close in Q3 2026
source ↗
◆Quarterly UpdateCorporate
Conference call and webcast to discuss Q1 2026 financial results and business update
source ↗
◆Quarterly UpdateCorporate
First quarter 2026 financial results release
source ↗
◆AcquisitionCorporate
Pending acquisition by Angelini Pharma S.p.A. announced
source ↗
▲Hatch Waxman LitigationFIRDAPSEApprovedIP / Competition
Settlement of FIRDAPSE patent litigation with Hetero Labs Ltd.
rare diseasessource ↗
▲IP Litigation RulingFIRDAPSEApprovedIP / Competition
Resolved patent litigation with Hetero regarding FIRDAPSE
Lambert-Eaton myasthenic syndromesource ↗
◆Oral PresentationPresentation
Catalyst Pharmaceuticals to present at Barclays 28th Annual Global Healthcare Conference
source ↗
◆Oral PresentationvamoroloneApprovedPresentation
MDA Industry Forum sponsored by Catalyst and Santhera on vamorolone
Duchenne muscular dystrophysource ↗
Unlock the full CPRX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CPRX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-05-30Firdapse (amifampridine phosphate) PDUFA Date ApprovedPDUFA
Unlock 14 more CPRX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Mar 2026; product lines: last four quarters to Mar 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
FIRDAPSE
AGAMREE
FYCOMPA
Showing 4 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Amifampridine Small moleculeMarketedNCT02562066Myasthenic Syndromes, CongenitalPhase 3 COMPLETED 20Oct 1, 2019
Amifampridine Small moleculeMarketedNCT01377922Lambert Eaton Myasthenic SyndromePhase 3 COMPLETED 64Jul 1, 2016
Amifampridine Small moleculeMarketedNCT03304054Myasthenia Gravis, GeneralizedPhase 3 COMPLETED 93Mar 15, 2020
Amifampridine Small moleculeMarketedNCT03781479Muscular Atrophy, SpinalPhase 2 COMPLETED 13Jul 23, 2020
Unlock the CPRX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CPRX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
AGAMREE® chronic inflammatory rare diseasesPhase 12026-07-01AGAMREE® shows less pronounced immunosuppressive biomarker effects; Clinically relevant immunosuppressive effects were observed only at the highest dose level; No relevant immunosuppressive effects were observed at lower dose levelsRead MoreSanthera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®Read More
Scroll for more · summaries link to the source press release
Unlock every CPRX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CPRX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Tierney David SDirectorDisposition -383,314 $31.50 07/15/2026
Unlock the full CPRX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in CPRX

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0.1 % (-50 %) 1.34 M 57.39 K -50.69% ( -59.00 K)
Unlock every fund holding CPRX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CPRX
Shares held by hedge funds each quarter, and who bought or sold.

CPRX Institutional Ownership Trends

CPRX Short Interest

Shares sold short, counted twice a month.

0.29%
Short % of Float
of tradable shares sold short
340.3K
Shares Sold Short
-95.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
3.0M
Avg Daily Volume
the average used for days to cover
Unlock CPRX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CPRX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CPRX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CPRX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CPRX ranks across every disease it competes in

Competitive Position is a premium feature
See how CPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CPRX News

About Catalyst Pharmaceuticals, Inc.

Coral Gables, FL 182 employees catalystpharma.com
Headquarters355 ALHAMBRA CIRCLE, CORAL GABLES, FL, 33134
BIOPHARMAWATCH ELITE PLUS
Trade the next CPRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime